In his latest PharmaTimes article, Dr Andrew Rut looks ahead to 2020 and outlines the trends we might well see emerge in the New Year. This includes the coming of age of precision medicines, where better insights into disease and earlier decision-making for precise targeting of interventions will be supported by high value and high volume adverse event data as part of programmes that enable patients to feedback adherence and safety data in real-time.
Read the full article here.
